Roche joins the M&A game, buy­ing gene ther­a­py pi­o­neer Spark for $4.3B

It’s of­fi­cial. Roche is join­ing the multi­bil­lion-dol­lar M&A game, ac­quir­ing a top play­er in the boom­ing gene ther­a­py busi­ness.

Im­age: Spark CEO Jef­frey Mar­raz­zo at an End­points News pan­el dur­ing the 2019 JP Mor­gan con­fer­ence Jeff Ru­mans for End­points News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER